The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. This presents a big opportunity for Guardant Health.Scientists have long hoped to have a way to diagnose cancer without having to obtain tissue samples. Guardant Health, Inc. GH 82.04 2.23 (2.65%). Fewer than 40% of patients with colorectal cancer are tested to guidelines. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The company estimates that the liquid biopsy test has a $6 billion addressable market in the U.S. Is that projection realistic? It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. The monthly returns are then compounded to arrive at the annual return. Their average twelve-month price target is $116.14The high price target for GH is $135.00 and the low price target for GH is $100.00. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. 8 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. In 2014, the company launched Guardant360, a liquid biopsy that helps match people who … A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. LUNAR-2 targets the detection of early-stage cancer.My view is that the buzz for Guardant Health will intensify over the next few years. Liquid biopsy, though, only requires a blood sample to be drawn. There are currently 8 buy ratings for the stock, resulting in … Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. This is done because, generally speaking, if an analyst reevaluates their earnings estimate right before an earnings release, it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago.The scores are based on the trading styles of Value, Growth, and Momentum. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.33% per year.
Guardant Health Inc. is based in REDWOOD CITY, United States.A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.Zacks Private Portfolio ServicesZacks Earnings ESP (Expected Surprise Prediction) looks to find earnings surprises by focusing on the most recent analyst revisions.
NASDAQ data is at least 15 minutes delayed.Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.Real time prices by BATS. Zacks Ranks stocks can, and often do, change throughout the month.
Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.NYSE and AMEX data is at least 20 minutes delayed.
Returns as of 07/30/2020.The potential annual market for LUNAR-1 could be around $15 billion.
The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.Guardant Health Inc. is a precision oncology company. LUNAR-1 targets recurrence detection in cancer survivors, as well as helping drugmakers identify new drug development opportunities in adjuvant and early-stage cancer settings.